Related Experiment Video
Updated: May 22, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
[Current status and problems of anti-HTLV-1 drug development]
Kazumi Nakano1, Toshiki Watanabe
1Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo.
Abstract:
HTLV-1 is one of the two pathogenic human retroviruses that causes adult T-cell leukemia(ATL), HTLV-1-associated myelopathy(HAM) and HTLV-1 uveitis (HU). Treatment of ATL is still very difficult today, thus search for new agents that target specific molecules are under way. For treatment of HAM and HU, suppression of HTLV-1 replicationappears to be important, as well as prevention of ATL development. Considering the common characteristics as human retroviruses, application of anti-HIV drugs appears to be a reasonable strategy, although it is not yet clinically tested for HTLV-1. Research of agents specific to HTLV-1 viral products needs to be encouraged to develop HTLV-1-specific anti-viral agents.

